GAIN THERAPEUTICS, INC Cash and Restricted Cash
GAIN THERAPEUTICS, INC (GANX) had Cash and Restricted Cash of $13.12 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.12M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.58M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.87M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.84M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $13.12M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $16.58M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $20.87M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $8.84M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $6.73M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $9.10M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $10.42M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $12.08M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $16.97M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $10.67M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $11.83M 10-K · filed 2026-03-26 |
| 2023-09-30 | $4.30M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $6.35M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $6.02M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $7.34M 10-K · filed 2025-03-27 |
| 2022-09-30 | $10.91M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $14.34M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $34.37M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $36.91M 10-K · filed 2024-03-26 |
| 2021-09-30 | $41.01M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $43.20M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $46.64M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $7.50M 10-K · filed 2023-03-23 |
| 2020-09-30 | $9.28M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $513.60K 10-Q · filed 2021-08-12 |
| 2020-03-31 | $945.11K 10-Q · filed 2021-05-10 |
| 2019-12-31 | $313.70K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |